Factory Mutual Insurance Co. lowered its position in shares of Allergan PLC. (NYSE:AGN) by 1.4% during the second quarter, Holdings Channel reports. The firm owned 500,700 shares of the company’s stock after selling 7,000 shares during the period. Allergan PLC. makes up about 1.4% of Factory Mutual Insurance Co.’s holdings, making the stock its 11th largest position. Factory Mutual Insurance Co.’s holdings in Allergan PLC. were worth $121,715,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. GWM Advisors LLC raised its position in Allergan PLC. by 0.4% in the first quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock valued at $300,000 after buying an additional 5 shares during the last quarter. Burns J W & Co. Inc. NY raised its position in Allergan PLC. by 0.7% in the second quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock valued at $220,000 after buying an additional 6 shares during the last quarter. Trust Co raised its position in Allergan PLC. by 0.8% in the first quarter. Trust Co now owns 1,224 shares of the company’s stock valued at $292,000 after buying an additional 10 shares during the last quarter. JNBA Financial Advisors raised its position in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the last quarter. Finally, Tarbox Group Inc. raised its position in Allergan PLC. by 0.6% in the first quarter. Tarbox Group Inc. now owns 2,393 shares of the company’s stock valued at $572,000 after buying an additional 15 shares during the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.

Allergan PLC. (NYSE:AGN) traded down 0.213% during trading on Tuesday, reaching $232.145. The company had a trading volume of 594,743 shares. The firm has a 50-day moving average of $245.54 and a 200-day moving average of $238.65. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The stock has a market capitalization of $77.61 billion, a price-to-earnings ratio of 7.073 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last released its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same quarter in the prior year, the firm earned $3.35 EPS. The company’s revenue was up 8.8% compared to the same quarter last year. On average, analysts anticipate that Allergan PLC. will post $16.27 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be given a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.20%. Allergan PLC.’s payout ratio is 9.95%.

WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/allergan-plc-agn-shares-sold-by-factory-mutual-insurance-co/1490762.html.

Several research analysts have recently commented on the company. UBS AG reissued a “buy” rating and issued a $275.00 price target on shares of Allergan PLC. in a research report on Monday, May 15th. Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price target for the company in a research report on Monday, June 26th. Wells Fargo & Company reissued an “outperform” rating and issued a $280.00 price target (up from $270.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. Argus reissued a “buy” rating and issued a $280.00 price target on shares of Allergan PLC. in a research report on Monday. Finally, Goldman Sachs Group, Inc. (The) lowered Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target for the company. in a research report on Wednesday, May 10th. Eight analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $275.49.

In other news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.36% of the stock is owned by corporate insiders.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.